Literature DB >> 6418828

Modulation of natural killer cell activity in patients with atopic dermatitis.

J R Jensen, T T Sand, A S Jørgensen, K Thestrup-Pedersen.   

Abstract

The peripheral blood lymphocytes of 36 adult patients with moderate to severe atopic dermatitis had reduced natural killer (NK) cell activity when measured against 51Cr-labeled K 562 cells. The decrease in NK cells activity was not related to the serum IgE level, but was related to the severity of the skin disease. Addition of autologous monocytes of the assay reduced the NK cell activity and concealed the enhancing effect of gamma-interferon addition in a 4-h assay. The NK cell activity of lymphocytes could be reduced in vitro by addition of prostaglandin E1, or increased by addition of gamma-interferon similar to lymphocytes from persons without atopic disease. Our present findings raise the possibility that the reduced NK cell activity may be secondary to the skin disease, and due to in vivo interaction between NK cells and monocytes, or to low numbers of NK cells in peripheral blood.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6418828     DOI: 10.1111/1523-1747.ep12259055

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  13 in total

1.  Evidence that defective interferon-gamma production in atopic dermatitis patients is due to intrinsic abnormalities.

Authors:  U Reinhold; W Wehrmann; S Kukel; H W Kreysel
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

2.  Depressed lymphocyte transformation and the role of prostaglandins in atopic dermatitis.

Authors:  T Jakob; B N Huspith; Y E Latchman; R Rycroft; J Brostoff
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

3.  Decreased natural killer cell activity in atopic eczema.

Authors:  T J Hall; R Rycroft; J Brostoff
Journal:  Immunology       Date:  1985-10       Impact factor: 7.397

4.  Defective natural killer cell activity in a mouse model of eczema herpeticum.

Authors:  Yuko Kawakami; Tomoaki Ando; Jong-Rok Lee; Gisen Kim; Yu Kawakami; Tae Nakasaki; Manando Nakasaki; Kenji Matsumoto; Youn Soo Choi; Toshiaki Kawakami
Journal:  J Allergy Clin Immunol       Date:  2016-07-29       Impact factor: 10.793

5.  Production of interferon and lymphoproliferative response in whole blood cultures derived from patients with atopic dermatitis.

Authors:  A Kapp; R Gillitzer; H Kirchner; E Schöpf
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

6.  Smallpox vaccine safety is dependent on T cells and not B cells.

Authors:  Shari N Gordon; Valentina Cecchinato; Vibeke Andresen; Jean-Michel Heraud; Anna Hryniewicz; Robyn Washington Parks; David Venzon; Hye-kyung Chung; Tatiana Karpova; James McNally; Peter Silvera; Keith A Reimann; Hajime Matsui; Tomomi Kanehara; Yasuhiko Shinmura; Hiroyuki Yokote; Genoveffa Franchini
Journal:  J Infect Dis       Date:  2011-04-15       Impact factor: 5.226

7.  Natural and concanavalin A-induced cytotoxic activity towards continuously growing B lymphocytes derived from patients with cutaneous T-cell lymphoma.

Authors:  J R Jensen; K Kaltoft; S Bisballe; K Thestrup-Pedersen
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

8.  Defective monocyte and polymorphonuclear leukocyte chemotaxis and clinical characteristics in atopic dermatitis.

Authors:  T Ternowitz; T Herlin
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

9.  Reduced interferon-gamma (IFN-gamma) secretion with increased IFN-gamma mRNA expression in atopic dermatitis: evidence for a post-transcriptional defect.

Authors:  M L Tang; G Varigos; A S Kemp
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

10.  Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum.

Authors:  Yuko Kawakami; Yoshiaki Tomimori; Kenji Yumoto; Shunji Hasegawa; Tomoaki Ando; Yutaka Tagaya; Shane Crotty; Toshiaki Kawakami
Journal:  J Exp Med       Date:  2009-05-25       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.